title: Obesity, immunomodulation and chronic kidney disease.
abstract: Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.
authors.affiliation: Center for Renal Translational Medicine, Division of Nephrology-Hypertension, Department of Medicine, Institute for Metabolomic Medicine, University of California San Diego, La Jolla, CA, United States.
authors.forename: Emma
authors.initials: E
authors.lastname: Börgeson
authors.forename: Kumar
authors.initials: K
authors.lastname: Sharma
mesh_terms: D000273:Adipose Tissue / Q000276:immunology; D000818:Animals; D006801:Humans; D056747:Immunomodulation; D007249:Inflammation; D009765:Obesity / Q000276:immunology*; D051436:Renal Insufficiency, Chronic / Q000276:immunology*